2. Amyotrophic lateral sclerosis Clinical trials / Disease details
Clinical trials : 624 / Drugs : 611 - (DrugBank : 160) / Drug target genes : 172 - Drug target pathways : 225
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00355576 (ClinicalTrials.gov) | July 2006 | 21/7/2006 | Combination Therapy Selection Trial in Amyotrophic Lateral Sclerosis | Phase II Combination Therapy Selection Trial in Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | Drug: Celecoxib;Drug: Creatine;Drug: Minocycline | Columbia University | ALS Association;Pfizer | Completed | 21 Years | 85 Years | Both | 86 | Phase 2 | United States |
| 2 | NCT00047723 (ClinicalTrials.gov) | January 2003 | 16/10/2002 | Minocycline to Treat Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | Drug: minocycline | National Institute of Neurological Disorders and Stroke (NINDS) | NULL | Completed | 21 Years | 85 Years | Both | 400 | Phase 3 | United States |